BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/12/2026 8:14:57 AM | Browse: 0 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 117115
Country China
Category Gastroenterology & Hepatology
Manuscript Type Randomized Clinical Trial
Article Title Efficacy and safety of lansoprazole combined with flupentixol-melitracen for functional dyspepsia: A randomized, double-blinded, placebo-controlled clinical trial
Manuscript Source Unsolicited Manuscript
All Author List Xin-Yuan Wang, Ke-Han Yin, Li Cheng, Xiao-Yu Wang, Ying Qiao, Xing-Ru Tang, Bo Wang, Xiu-Juan Yan and Sheng-Liang Chen
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 82570628
National Natural Science Foundation of China 82170554
National Natural Science Foundation of China 82300643
Corresponding Author Sheng-Liang Chen, Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China. chenslmd@shsmu.edu.cn
Key Words Flupentixol-melitracen; Functional dyspepsia; Lansoprazole; Anxiety; Deanxit
Core Tip This randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of flupentixol-melitracen combined with lansoprazole for functional dyspepsia (FD). our study demonstrated that this low-dose short-term regimen not only improved FD symptoms and quality of life within two weeks but also sustained efficacy for four weeks post-treatment. Future long-term follow-up and multicenter studies are warranted to verify its lasting benefits and health economic value, potentially advancing FD management from a “stepwise sequential” approach to a “brain-gut co-management” therapy.
Citation Wang XY, Yin KH, Cheng L, Wang XY, Qiao Y, Tang XR, Wang B, Yan XJ, Chen SL. Efficacy and safety of lansoprazole combined with flupentixol-melitracen for functional dyspepsia: A randomized, double-blinded, placebo-controlled clinical trial. World J Gastroenterol 2026; In press
Received
2025-12-01 01:07
Peer-Review Started
2025-12-01 01:07
First Decision by Editorial Office Director
2026-01-07 09:24
Return for Revision
2026-01-07 09:24
Revised
2026-01-19 10:22
Publication Fee Transferred
2026-01-20 13:07
Second Decision by Editor
2026-02-12 02:41
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-02-12 08:14
Articles in Press
2026-02-12 08:14
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com